A Resilience Building Intervention to Promote Successful Aging (RISE)

In this pilot study, a pre-post experimental design will be used, in which 60 community dwelling adults aged 50+ will recruited from a larger parent study, and will then be randomized to either a no-contact control or intervention condition. Those in the intervention condition will receive a psychoeducational intervention in which they will receive scientific literature-based information on resilience and strategies to bolster resilience, as well as developing an individualized plan on areas to engage in at home over the next four weeks. All participants will return for an immediate posttest using an abbreviated version of the baseline battery from the parent study.

Study Overview

• Status: Completed
• Conditions: Community Dwelling Adults Aged 50 and Older
• Intervention / Treatment: Behavioral: Pilot Resilience Building Intervention

• Study Type: Interventional
• Enrollment (Actual): 61
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • the Holly Mears Building/Center for Research on Applied Gerontology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria/Exclusion Criteria:

• Must be enrolled in a larger parent study
• The criteria for the parent study are: no neurological or severe neuromedical disorders (e.g., stroke, schizophrenia), must be able to speak English, not be legally blind or deaf, not currently undergoing chemotherapy or radiation therapy, no brain trauma with loss of consciousness greater than 30 mins, and not homeless.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: No contact control; the no contact control group will do nothing
Experimental: Intervention; the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks	Behavioral: Pilot Resilience Building Intervention; The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Resilience	Connor Davidson Resilience Scale	4 weeks

Collaborators and Investigators

• Sponsor: University of Alabama at Birmingham

Study record dates

Study Major Dates

• Study Start (Actual): April 13, 2018
• Primary Completion (Actual): March 31, 2019
• Study Completion (Actual): March 31, 2019

Study Registration Dates

• First Submitted: September 22, 2017
• First Submitted That Met QC Criteria: September 22, 2017
• First Posted (Actual): September 27, 2017

Study Record Updates

• Last Update Posted (Actual): April 3, 2019
• Last Update Submitted That Met QC Criteria: April 1, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: Wheeler SON DSA

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No